Body size-adjusted dose analysis of pirfenidone in patients with interstitial pneumonia.

about

Treatment doses in idiopathic pulmonary fibrosis: The devil is in the detail.

P2860

Q47738297-4687AC7B-6D3F-4194-9465-92590CC578A9

P2860

Body size-adjusted dose analysis of pirfenidone in patients with interstitial pneumonia.

Item

http://www.wikidata.org/entity/Q47191410

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Body size-adjusted dose analysis of pirfenidone in patients with interstitial pneumonia.

@en

Body size-adjusted dose analysis of pirfenidone in patients with interstitial pneumonia.

@nl

type

Item

label

Body size-adjusted dose analysis of pirfenidone in patients with interstitial pneumonia.

@en

Body size-adjusted dose analysis of pirfenidone in patients with interstitial pneumonia.

@nl

prefLabel

Body size-adjusted dose analysis of pirfenidone in patients with interstitial pneumonia.

@en

Body size-adjusted dose analysis of pirfenidone in patients with interstitial pneumonia.

@nl

P1476

Body size-adjusted dose analysis of pirfenidone in patients with interstitial pneumonia

@en

P2093

Kazuki Furuhashi

http://www.w3.org/2001/XMLSchema#string

Masahiro Uehara

http://www.w3.org/2001/XMLSchema#string

Masato Kono

http://www.w3.org/2001/XMLSchema#string

Naoki Inui

http://www.w3.org/2001/XMLSchema#string

Takafumi Suda

http://www.w3.org/2001/XMLSchema#string

Yoshiyuki Oyama

http://www.w3.org/2001/XMLSchema#string

Yutaro Nakamura

http://www.w3.org/2001/XMLSchema#string

P2860

Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.

Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model.

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis.

Pharmacokinetic and pharmacometabolomic study of pirfenidone in normal mouse tissues using high mass resolution MALDI-FTICR-mass spectrometry imaging.

Clinical course and prediction of survival in idiopathic pulmonary fibrosis.

P304

318-324

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/RESP.13145

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yuzo Suzuki

Noriyuki Enomoto

Tomoyuki Fujisawa

P577

2017-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28851013

http://www.w3.org/2001/XMLSchema#string

Body size-adjusted dose analysis of pirfenidone in patients with interstitial pneumonia.

about

P2860

P2860

Body size-adjusted dose analysis of pirfenidone in patients with interstitial pneumonia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698